Imugene
高管
查看带有其 16 名主要高管的组织结构图
Imugene 搜索最多的简介
- Leslie Chong, Director, Chief Executive Officer and Director
- Jakob Dupont, Non-Executive Director
- Jens Eckstein, Non-Executive Director
高管在Imugene变化
- John Byon已作为Senior Vice President, Clinical Development加入公司 (新闻发布的2023九月6号).
- Paul Woodard已作为Chief Medical Officer加入公司 (新闻发布的2023九月5号).
- Bradley Glover已作为Chief Operating Officer加入公司 (新闻发布的2023八月21号).
创建提醒
跟踪 Imugene 的高管变动
生物技术
Imugene 拥有 2,284 家竞争者，其中包括 Lonza (瑞士)、Eurofins (卢森堡) 和 Adaptive Phage Therapeutics (美国(美洲))。
Popular M&A news in 生物技术
- Karius 刚刚宣布为 100 筹款数百万美元。 (公布2024五月3号).
- Transcarent 刚刚宣布为 126 筹款数百万美元。 (公布2024五月2号).
- WindRose Health Investors has announced the acquisition of SubjectWell (公布2024五月2号).
生物技术 行业的其他推荐联系人
消息
Imugene 的最新新闻稿
- Imugene has VAXINIA technology selected for presentation at Cholangiocarcinoma Foundation conference
- Imugene shines at AACR with promising cancer therapy results from VAXINIA and HER-Vaxx
- Imugene and Kincell Bio form manufacturing and process development partnership
- Imugene granted China patent for Oncolytic Virotherapy CF33
- Imugene expands bile tract cancer study as patient shows complete response during MAST trial phase
- Imugene with Proactive at ASX Small and Mid Cap Conference
- Biotech around the World: The Low-Down on the Land Down Under
- Imugene presents CF33-hNIS oncolytic virus study details at ASCO-GI Cancers Symposium
- Imugene receives positive early results, including a 'complete response', in Phase 1 VAXINIA study
- Imugene’s Phase 1 onCARlytics clinical trial doses first patient in intravenous monotherapy arm
- View more press releases Close
通过电子邮件
